Novo Nordisk continues to deliver strong revenue, profit growth, and high economic profitability. Read why I rate NVO stock a ...

Ozempic helped Novo Nordisk gain an early lead in the weight loss industry, but competition is nipping at the company's heels ...

The Danish drugmaker unveiled a series of initiatives to increase access to Wegovy and clamp down on use of the knock-off ...

Somapacitan was noninferior to somatropin in improving yearly growth rate in ... According to Novo Nordisk, results from the TS substudy will be available later this year. Regulatory submission for ...

which may better suit the needs of children with growth failure. These encouraging results from REAL8 mark a significant step forward in achieving that commitment.” 1 In April 2025, Novo Nordisk ...

Collaboration combines Novo Nordisk's scientific leadership in obesity and cardiometabolic diseases with Septerna's expertise in G protein-coupled receptor (GPCR) drug discovery Goal is to develop ...

Results from the Phase III REAL8 basket study show that Novo Nordisk’s Sogroya (somapacitan) demonstrated significant efficacy and was well-tolerated in children with growth disorders, including those ...

COPENHAGEN, May 14 (Reuters) - Novo Nordisk has struck a collaboration ... processes such as metabolism, secretion, cell growth, and immune responses. The two companies aim to commence four ...

Novo Nordisk ... inferior to the once-daily growth hormone Norditropin (somatropin) in improving yearly growth rate (as measured by height velocity [HV] at Week 52) in pre-pubertal children born small ...

With a late-stage trial win for its Norditropin heir in hand, Novo Nordisk ... s daily growth hormone in children with Noonan syndrome (NS) and in children born small for gestational age (SGA ...